TNX-1500
Organ Transplant Rejection / Autoimmune Disorders
Phase 1Clinical phase complete; Phase 2 ready
Key Facts
Indication
Organ Transplant Rejection / Autoimmune Disorders
Phase
Phase 1
Status
Clinical phase complete; Phase 2 ready
Company
About Tonix Pharmaceuticals
Tonix Pharmaceuticals is a patient-focused biotechnology company dedicated to developing impactful treatments for complex, chronic conditions that defy easy answers, including nociplastic pain, immunology/immuno-oncology, and infectious diseases. Its strategy leverages an integrated clinical development engine to advance a diverse pipeline, with key programs like TNX-102 SL for acute stress disorder expected to report Phase 2 topline data in the second half of 2026. The company's mission is to empower patients to live fully through scientific rigor and a deep respect for the patient experience, supported by a leadership team with significant industry expertise.
View full company profile